Whether high-risk features (HRFs) on the recurrence or microsatellite instability (MSI) status are predictive markers for adjuvant chemotherapy (ACT) in patients with stage II colon cancer is uncertain. This study aimed to examine the impact of HRFs and MSI on the prediction of the benefits of ACT in patients with stage II colon cancer. This multi-center retrospective study included 1801 patients with resected stage II colon cancer diagnosed at 17 university-affiliated hospitals between January 2010 and December 2017.
Not Applicable
Active, not recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0009579
- Lead Sponsor
- Keimyung University Dongsan Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 1300
Inclusion Criteria
patients with resected stage II colon adenocarcinoma
Exclusion Criteria
synchronous or previous malignancies, R1 or R2 resection, irinotecan-based ACT, or targeted therapy
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 5-year survival rate
- Secondary Outcome Measures
Name Time Method patient characteristics, pathologic outcomes